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Immunosuppression for human 
saphcnous vein allograft bypass surgery: 
A prospective randomized trial 
Jeffrey P. Carpenter, MD, and John E. Tomaszewski, MD, Philadelphia, Pa. 
Purpose: Vein allografts are an alternative bypass conduit for patients who lack adequate 
autogenous vein. Animal studies have demonstrated that patency can be augmented by 
low-dose hnmunosuppression with azathioprine. 
Methods: In a prospective trial, 40 patients (20 men, 20 women) were randomly assigned 
to receive (17) or to not receive (23) azathioprine (1 mg/kg/day) after cryopreserved 
vein allograft bypass grafting. Patients had pain or tissue loss that required bypass 
grafting to pedal or crural outflow and lacked adequate autogenous saphenous vein. 
Anti-HLA antibody screens were obtained before and after surgery. Biopsies of allografts 
were performed at implantation and at all subsequent opportunities. Postoperative 
physical and vascular laboratory examinations occurred every 3 months. 
Results: During the 31-month follow-up interval (mean, 15.7 months) there were 10 
deaths (none immunosuppression-related). The primary graft patency rate at 12 months 
was 13%, and the limb salvage rate was 42%. No significant difference (p > 0.05) was 
noted between immunosuppressed and control groups for mortality rate, primary graft 
patency rate, or limb salvage rate. As a predictor of graft failure, positive preoperative 
anti-HLA antibody screen (8 patients) approached significance (p = 0.09). Of 22 
explanted grafts, 13 (59%) had histologic evidence of rejection (six immunosuppressed, 
seven control). Seven patients who had negative resuits of preoperative anti-HLA anti- 
body screens converted after surgery, and six patients had positive results of preoperative 
screens that became more strongly positive. 
Conclusion: Vein allograft failure is in part mediated by rejection, which is not eliminated 
by low-dose azathioprine. Both humoral (antibody) and cellular responses to vein 
allografts develop. The poor patency rates of vein allograft bypass grafts may be improved 
by more potent immunosuppression as well as improvement in allograft procurement, 
preservation, and matching. (J Vasc Surg 1997;26:32-42.) 
For patients who require lower extremity periph- 
eral bypass urgery, autogenous saphenous vein is the 
graft material of choice. When autogenous saphe- 
nous vein is not available, alternative conduits uch as 
arm veins, 1 lesser saphenous veins, and prosthetic 
bypass grafts 2,3 must be considered. The long-term 
patency rate of synthetic grafts, especially in small 
arteries, is poor, a,4 owing in part to the absence of an 
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endothelial lining. Vein aUografts would provide an 
attractive substitute for autogenous saphenous vein if 
rejection did not alter them and lead to occlusion. 
Experience with human saphenous vein allografts has 
yielded varied results, sq4 The series previously re- 
ported are retrospective and contain mixed popula- 
tions of patients, vein allograft procurement and 
preservation techniques, surgical indications, and 
outcomes. 
Transplant rejection plays a role in the failure of 
vein allografts, is although the details of this process 
arc as yet unclear. Experimental evidence in animals 
has shown improved patency rates of vein allografts 
using the potent immunosuppressive drug, cyclo- 
sporinc. 16-23 Other canine studies have demonstrated 
that even low-dose immunosuppression with the rel- 
atively safe agent azathioprine significantly prolongs 
the patency of vein allografts. 24 The efficacy of im- 
munosuppression f human vein allograft recipients 
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is unknown. The purpose of this study was to exam- 
ine the effect of low-dose immunosuppression with 
azathioprine on human saphenous vein allograft by- 
pass recipients in the context of a prospective, con- 
trolled, randomized trial. 
METHODS 
A prospective, randomized, controlled, parallel 
group study was designed to investigate all patients 
of a single surgeon (JPC) who underwent vascular 
surgical bypass procedures for limb threatening isch- 
emia and lacked adequate autogenous aphenous 
vein. This study was approved by the Institutional 
Review Board of the University of Pennsylvania 
School of Medicine. 
Inclusion criteria. Patients included met the 
following criteria: (1) patients had SVS/ISCVS class 
III, grade 4 or 5 ischemia, 2a which includes patients 
with ischemic rest pain, tissue loss, or both; 2) pa- 
tients lacked adequate available autogenous greater 
saphenous vein; (3) patients had an anticipated pe- 
ripheral bypass procedure from a suprageniculate in-
flow artery to an infrageniculate outflow artery; (4) 
patients provided written informed consent o ran- 
domization; (5) patients were willing to undergo 
preoperative and follow-up evaluations and were 
willing to be compliant with study medication ad- 
ministration. 
Exclusion criteria. Patients were excluded by 
the following criteria: (1) patients who were receiv- 
ing treatment with an immunosuppressive drug; (2) 
patients who were receiving dialysis; (3) patients with 
a history of malignancy; (4) patients who had re- 
ceived a solid organ transplant or prior vein allograft; 
(5) patients who were receiving treatment with war- 
farin; (6) women of child-bearing potential; (7) pa- 
tients with rheumatoid arthritis previously treated 
with alkylating agents (because of the prohibitive risk 
of neoplasia if treated with azathioprine); (8) patients 
with a coexisting medical, psychologic, or sociologic 
condition that would preclude any of the treatment 
or follow-up procedures. 
Preoperative testing. All patients underwent 
complete preoperative contrast artcriographic exam- 
ination from the aorta through pedal arteries. In 
addition, all patients underwent preoperative pulse 
volume recordings (PVR) and segmental pressure 
measurements, including the recording of a preoper- 
ative ankle-brachial index (ABI). Vein allograft recip- 
ients underwent preoperative screening for anti- 
HLA antibodies. 
Vein allografts. Cryopreservcd saphenous vein 
allografts were obtained from Cryolife Cardiovascu- 
lar, Inc. (Marietta, Ga.). Veins were stored in a di- 
methyl sulfoxide-containing solution a t -196  ° C. 
Single-donor veins only (no composite allografts) 
were used. All grafts were ABO blood group- 
matched to the recipient. Vein allograft outer diam- 
eters were never less than 4 mm. The storage, thaw- 
ing, and handling protocols for use of cryopreserved 
saphenous vein allografts as provided by Cryolife 
Cardiovascular, Inc., were strictly followed. At the 
time of the operative procedure, a segment of each 
implanted vein was obtained as a biopsy specimen 
and stored for pathologic examination. Intraoper- 
ative postbypass arteriograms were obtained to as- 
sure the technical adequacy of each operative pro- 
cedure. 
Study drugs. All patients received aspirin, 325 
mg per day, beginning the night before implantation 
of the vein allograft. Patients who were randomized 
to receive azathioprine were given a 5 mg/kg intra- 
venous bolus during surgery immediately before im- 
plantation of the vein allograft and after surgery at an 
oral dose of 1 mg/kg/day. Azathioprine administra- 
tion continued until the conclusion of the follow-up 
interval or failure of the vein allograft. 
Randomization. Balanced randomization was 
used by means of a randomization table. Participa- 
tion in the study was offered to all patients who were 
considered to meet the entry criteria. No eligible 
patients refused participation. 
Vascular follow-up studies. Pulse volume re- 
cordings and segmental pressure measurements, as 
well as duplex Doppler imaging of vein allografts 
with velocity measurements, were performed imme- 
diately after surgery and every 3 months until the 
conclusion of the follow-up interval or failure of the 
vein allograft. Physical examination of the patient 
was also performed every 3 months at minimum. 
Immunologic follow-up studies. Anti-HLA 
antibody screens were performed on blood samples 
taken at 3 days and 3 weeks after implantation of the 
vein allograft. Studies were also obtained at the time 
of allograft failure. A positive study was defined as 
any study in which anti-HkA antibodies were de- 
tected against a standard panel of antigens and the 
percentage ofreactive antibodies was reported. Biop- 
sies of implanted vein allografts were performed at 
any opportunity subsequent to implantation (such as 
thrombectomy, revision, amputation). Patients who 
received azathioprine underwent monitoring of their 
complete blood counts and liver function. 
Histologic analysis. Standard hematoxylin and 
eosin preparations of implanted and explanted allo- 
grafts were prepared, as well as standard immunohis- 
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Fig. 1. Life-table analysis of primary graft patency data of immunosuppressed (n = 17) and 
control (n = 23) patients who received saphenous vein allograft bypass grafts. No significant 
difference between the immunosuppressed and control groups was identified for primary graft 
patency. Error bars represent the standard error. 
Tab le  I.  Patient characteristics 
Characteristic Immunosnppressed % Control % Significance 
Sex Male, 9 53 Male, 11 48 NS 
Female, 8 47 Female, 12 52 
Age Mean, 68.6 Mean, 66.9 NS 
Range, 45 to 84 Range, 43 to 86 
Diabetes 14 82 16 70 NS 
Hypertension 14 82 18 78 NS 
Smoking 13 76 15 65 NS 
Coronary artery disease/prior MI 14 82 12 52 NS 
Prior stroke 1 6 3 13 NS 
Renal insutficiency (Cr > 1.5 mg/dl) 3 18 10 43 NS 
Prior vascular surgery 15 88 21 91 NS 
Rest pain (class III, grade 4) 6 35 4 17 NS 
Tissue loss (class III, grade 5) 11 65 19 83 NS 
Preoperative ABI Mean, 0.06 Mean, 0.10 NS 
Range, 0,00 to 0.47 Range, 0.00 to 0.58 
Saphenous inadequate due to prior: Leg bypass, 12 Leg bypass, 17 NS 
Coronary bypass, 11 Coronary bypass, 8 NS 
Amputation, 1 Amputation, 6 NS 
Phlebitis, 1 Phlebitis, 2 NS 
Cr, Creatinine level. 
tochemical methods used for investigation of  ex- 
p lanted allografts. 
Eva luat ion  o f  efficacy. Patients were moni tored 
for vein allograft patency, l imb salvage, pat ient sur- 
vival, occurrence of  complications, development of  
host antibodies and histopathologic evidence ofa l lo-  
graft rejection as well as adverse drug reactions, and 
all data were entered into a database. All vascular 
efficacy data were recorded in the form suggested by 
the Ad Hoc  Report ing Standards Commit tee  of  the 
SVS/ISCVS.2S 
Stat ist ica l  analysis.  Vein allograft patcncy, l imb 
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Fig. 2. Life-table analysis of limb salvage data for immunosuppressed (n = 17) and control 
(n = 2 3) patients who received saphenous vein allograft bypass grafts. No significant difference 
was found between immunosuppressed and control groups for limb salvage rate. Error bars 
represent the standard error. 
Tab le  I I .  Operative characteristics 
Characteristic Immunosuppressed % Control % Significance 
Anesthetic General, 13 76 General, 19 83 NS 
Epidural, 4 24 Epidural, 5 22 NS 
Inflow artery Common femoral, 8 47 Common femoral, 10 43 NS 
Deep femoral, 2 12 Deep femoral, 8 35 NS 
Superficial femoral, 4 24 Superficial femoral, 4 17 NS 
External i iac, 3 18 External i iac, 1 4 NS 
Outflow artery Peroneal, 5 29 Peroneal, 7 30 NS 
Anterior tibial, 7 41 Anterior tibial, 4 17 NS 
Posterior tibial, 3 18 Posterior tibial, 5 22 NS 
Dorsalis pedis, 1 6 Dorsalis pens, 5 22 NS 
Popliteal (below-knee), 1 6 Popliteal (below-knee), 2 9 NS 
No. runoffvessels patent Mean, 1.23 Mean, 1.13 NS 
Range, 1 to 3 Range, 1 to 2 
Pedal arch Continuous, 4 24 Continuous, 8 35 NS 
Discontinuous, 13 76 Discontinuous, 13 65 NS 
Age of vein donor Mean, 36 Mean, 38.4 NS 
Range, 19 to 58 Range, 15 to 61 
salvage rates, and patient survival rates were deter- 
mined by the life table method.  Differences between 
groups were tested for significance using Student 's  t 
test for cont inuous variables and ×2 or Fisher's exact 
test for categorical variables. Life table methods and 
log-rank testing were used for comparisons o f  pa- 
tency, mortal ity, and l imb salvage data. Differences 
between groups were considered significant for p 
values less than 0.05, and all tests were two-sided. 
RESULTS 
Demograph ics .  Forty patients (20 men, 20 
women)  were enrol led over a 24-month  per iod and 
were observed for 31 months (mean, 15.7 months) .  
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Fig. 3. Development ofanfi-HLA antibodies after vein allograft bypass grafting in 38 patients. 
The development of anti-HLA antibodies for individual patients after the bypass procedures 
suggests ahumoral immune response to the allograft and implies the antigenicity of the bypass 
graft. 
No patients were lost to follow-up. During this same 
interval 130 autogenous vein bypass procedures were 
performed by the author (JPC). Characteristics and 
comorbid conditions of patients in both the immu- 
nosuppressed and control groups, as well as the fate 
of their autogenous saphenous veins, are presented 
in Table I. No significant differences were found 
between these two groups for any demographic vari- 
able. Groups were comparable with respect o co- 
morbid conditions and indications for surgery as well 
as preoperative ABI. Characteristics of the operative 
procedures performed for the immunosuppressed 
and control groups are shown in Table II. No signif- 
icant differences were found between the immuno- 
suppressed and control groups with respect o the 
status of inflow or outflow vessels, run-off, anesthetic 
technique, or age of allograft vein donor. 
Mortal ity data. During the 31-month fol- 
low-up interval there were 10 deaths, caused by myo- 
cardial infarction in 4, congestive heart failure in 1, 
malignancy in 1, and unknown causes in 4. No 
deaths were believed to be related to immunosup- 
pression. One death occurred in the 30-day periop- 
erative period: a fatal myocardial infarction on post- 
operative day one. No significant difference between 
immunosuppressed patients and control patients for 
life table analysis of mortality data was found. 
Graft  patency and limb salvage. The cumula- 
tive primary graft patency rate at 12 months was 13%. 
No significant difference was found between immu- 
nosuppressed and control groups in terms of primary 
graft patency rate (Fig. 1). The cumulative limb sal- 
vage rate at 12 months was 42%. No significant 
difference was found between immunosuppressed 
and control groups for limb salvage (Fig. 2). 
Ant i -HLA antibodies. Preoperative anti-HLA 
antibody screens were available for 38 patients before 
surgery; eight had positive results and 30 had nega- 
tive results. Seven patients who had negative results 
on the anti-HLA antibody screens (23%) had positive 
results after surgery. Of those who converted, one 
converted as early as 3 days after surgery. The re- 
mainder converted between 3 weeks and 6 months 
after surgery (Fig. 3). Of the eight patients who had 
positive results on the anti-HLA antibody screens 
before surgery, six had more strongly positive results 
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Fig. 4. Comparison of primary graft patency in patients with anti-HLA antibodies (positive) 
vs. patients without anti-HLA antibodies (negative) detected before surgery. The presence of 
preoperative anti-HLA antibodies significantly predicted bypass graft failure at the 90% but not 
the 95% significance l vel. Error bars represent the standard error. 
in the follow-up interval. Two patients who had a 
positive result on the preoperative anti-HLA anti- 
body screen had a negative result after surgery. 
A subanalysis of preoperative status of anti-HLA 
antibodies for prediction of graft failure was per- 
formed (Fig. 4). A positive preoperative anti-HLA 
antibody screen resulted in poorer primary graft pa- 
tency rates than did a negative screen, but this result 
did not achieve significance (p = 0.09) at the 95% 
significance l vel. 
Histopathologic analysis. All vein allograft bi- 
opsies, both at the time of implantation and explan- 
tation, were reviewed by a single experienced trans- 
plant immunopathologist (JET) who was blinded to 
the status of patient immunosuppression. Biopsies 
from the time of implantation uniformly reflected 
some degree of preservation i jury with characteristic 
apoptosis in the outer layers of the vein allograft (Fig. 
5). The inner layers of the allograft and the endothe- 
lium appeared intact on all specimens. 
Of the 22 explanted grafts (10 immunosup- 
pressed, I2 control), 13 (59%) had histologic evi- 
dence of rejection (six immunosuppressed, seven 
control group). These patients demonstrated anin- 
flammatory infiltrate that was further characterized 
by immunohistochemical m rkers (Fig. 6). This infil- 
trate consisted predominately of T-lymphocytes 
(Fig. 6, B). Macrophages (Fig. 6, C) and B-lympho- 
cytes (Fig. 6, D) were less prevalent. 
Complications. Complications that occurred 
during the course of the trial are presented in Table 
III. There were seven wound infections, three of 
which required emergent graft removal as a result of 
dehisced vein allograft anastomoses. One patent 
graft was removed as a result ofaneurysmal degener- 
ation. There was no significance difference between 
immunosuppression a d conl:rol groups for occur- 
rence or severity of complications. 
DISCUSSION 
For many patients who have limb-threatening 
lower extremity ischemia, the availability of autoge- 
nous vein for vascular econstruction is limiting. In 
our series, 95% of patients had undergone prior cor- 
onary or peripheral bypass procedures and had re- 
turned for reoperative vascular surgery without ade- 
quate autogenous aphenous vein. Patients with 
severe ischemia usually require bypass grafts to crural 
or pedal vessels. In this setting, prosthetic bypass 
conduits have historically performed poorly, with 
1-year patency rates between 20% and 39%. 2.4 Low 
prosthetic patency rates have stimulated the search 
for alternative grafts. 
Experimentation with vein allografts as an arterial 
substitute has been pursued since Alexis Carrell's 
original description of a canine jugular vein allograft 
implanted into the aorta of a dog that remained 
patent for 2 years. 26 Prior human experience with 
venous allografts has yielded mixed results, with 
1-year patency rates ranging from 10% to 68% (Table 
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Fig. 5. Biopsy at the time of implantation fa saphenous 
vein allograft shows apoptosis of the outer layers of the 
smooth muscle. This i  thought o be a preservation/ 
procurement-related phenomenon. 
IV). s-14 All of these series are retrospective and are 
subject o the limitations of such reviews. Many of 
the series contain composite allografts consisting of 
several spliced segments. The method of allograft 
procurement and preservation used in these studies is 
often not uniform, and the patient populations are 
varied, with indications ranging from claudication to 
tissue loss and outflow ranging from normal to very 
poor. This has frustrated statistical analysis of these 
series and led to confusion regarding the actual per- 
formance of vein allografts in human beings. The use 
of immunosuppression for human saphenous vein 
allografts has not previously been reported. 
We performed a controlled, prospective, ran- 
domized trial using low-dose immunosuppression n 
patients who were receiving saphenous vein allografts 
for severe limb-threatening ischemia. The patient 
demographics and operative characteristics were 
equivalent in the two study groups in all respects. 
Table II I .  Complications 
Immunosuppressed Control 
Wound infection (superficial) 3 1 
Wound infection (requiting 2 i 
graft removal) 
Myocardial infarction - -  2 
Gastrointestinal hemorrhage - -  1 
Graft aneurysm 1 - -  
The study population reflects the patient population 
that would typically be considered for use of an 
alternative conduit; that is, patients with severe limb- 
threatening ischemia who returned for reoperative 
vascular surgery to compromised crural or pedal out- 
flow tracts. The severity of disease in our patient 
population is reflected by the 21% mortality rate at 1 
Year as well as the parallel relationship between graft 
patency and limb salvage rates, with a 58% rate of 
limb loss after allograft failure at 1 year. Many of our 
patients had subsequent arm-vein or prosthetic by- 
pass grafts implanted after allograft failure, which 
prevented an even higher rate of limb loss. 
We found a 12-month graft patency rate of only 
13% in this severely diseased population, which is 
clearly inferior to modern series of autogenous sa- 
phenous vein grafts. The cause of graft failure in the 
majority of cases appeared to be vein allograft rejec- 
tion. Although it was originally thought hat venous 
tissue may be only wealdy antigenic or nonanti- 
genie, 27 it has been demonstrated that venous tissue, 
and endothelium inparticular, expresses major histo- 
compatibility (MHC) class I and II antigens and 
non-MHC antigens that stimulate a T-cell-mediated 
rejection response, ls,24,28 Cryopreservation does not 
appear to significantly diminish this antigenicity. 
Cryopreservation itself is also known not to lead to 
an inflammatory esponse, as demonstrated in cryo- 
preserved canine autografts. 29We found evidence of 
a T-cell-mediated rejection response in our human 
subjects. 
Animal investigations have demonstratccl that the 
use of the potent immunosuppressant cyclosporine 
prolongs vein allograft survival in canines and in 
miniature swine) 6 23 Cyclosporine, however, is asso- 
ciated with nephrotoxicity and the infectious and 
neoplastic complications ofimmunosuppression. 3° A 
human study of renal transplant recipients receiving 
immunosuppressive th rapy with cyclosporine, aza- 
thioprinc, and prednisone in whom cryopreserved 
arterial allografts were implanted emonstrated the 
abscnce of rejection in two explantcd failcd allo- 
grafts, indicating that the use of potent immunosup- 
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Fig. 6. Human saphenous vein allograft rejection demonstrated in an explanted vein allograft. 
The inflammatory infiltrate (A) is demonstrated to be predominantly T-lymphocytes on this 
photomicrograph using a CD3 marker (B). Macrophages (C) and B-lymphocytes (D) are less 
prevalent (CD68 and L26 markers, respectively). 
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Table IV. Human vein allograft rials 
Patency rate 
Author Storage Preservation No. at 12 mo 
Ochsner et al. 1971 s Fresh No DMSO 22 45 (S) 
Tice et al. 19726 Frozen No DMSO 25 48 
Stephen et al. 19787 Cold Serum/heparin 1I 10 (P) 
Ochsner et al. 19848 Fresh, frozen Tanned 129 50 (S) 
Selke et al. 19899 Cryopreserved DMSO 6 33 (P) 
Martin et al. 1990 i° Cryopreserved DMSO 42 37 (P) 
Shah et al. 1993 ii Cryopreserved DMSO 43 66 (P) 
Harris et al. I99312 Cryopreserved DMSO 25 36 (P) 
Walker et al. 199313 Cryopreserved DMSO 39 14 (P) 
Gournier et al. 1995i4 Cryopreserved DMSO 20 68 (P) 
Present Series Cryopreserved DMSO 40 13 (P) 
P, Primary; S, secondary. 
pression may alter the rejection response in human 
subjects. 8~ Earlier canine experiments using the rela- 
tively safe immunosuppressive agent azathioprine 
have shown mixed results with respect o prolonga- 
tion of  allograft patency. 24,a2,33 We chose to use 
low-dose azathioprine with the hope that a signifi- 
cant effect could be demonstrated with minimal pa- 
tient immunosupprcssant risk. We found no signifi- 
cant difference with respect to graft patency and limb 
salvage rates between immunosuppressed and con- 
trol groups using the same immunosuppressive dos- 
age as was used in our earlier canine experiments. 
Histopathologic evidence of rejection was apparent 
even in the immunosuppressed patients. It is likely 
that with the use of more potent immunosuppressive 
agents, the rejection response could be decreased 
and allograft patency augmented. 
Others have shown that HLA matching of do- 
nors and recipients modulates vein allograft patency 
in miniature swine. 34 With the current pool of vein 
allograft donors, this is impractical in human beings, 
a situation analogous to liver transplantation. I  the 
future, however, this may be possible. We made no 
attempt o HLA type or match our patients and 
donors. 
In addition to cell-mediated immunity, we dem- 
onstrated a recipient antibody response to vein allo- 
grafts (Fig. 4). This attests to the antigenicity of 
cryopreserved vein allografts. 24,a5 The formation of 
anti-HLA antibodies was seen in many recipients, 
and those recipients who had anti-HLA antibodies 
present before implantation developed higher titers 
in the postoperative p riod. Formation of anti-HLA 
antibodies predicted graft failure at the 90% but not 
the 95% significance l vel. More potent immunosup- 
pressive therapy could depress this response as well as 
the cell-mediated immune response and potentially 
augment vein allograft patency. 
It is known that antiplatelet drugs improve vein 
allograft patency in animal experiments. 2],36 We 
chose to use aspirin for this reason. Experience with 
prosthetic grafts has demonstrated increased patency 
with the use of warfarin anticoagulation. 37 It is pos- 
sible that adjunctive use of warfarin could augment 
vein allograft patency as well. 
Cryopreservation f vein allografts allows ready 
access to a stored inventory of allografts that are 
immcdiately available for implantation when the 
need arises. Cryopreservation a d thawing results in 
a functional endothelium and vascular smooth mus- 
cle, and the endothelial cells have been demonstrated 
to grow in tissue culture after thawing. 36-43 This 
offers the potential advantage of an endothelial-lined 
conduit. 29,44 We saw some evidence of injury to the 
smooth muscle outer layers of vein allografts, but the 
innermost smooth muscle and endothelial ayer 
seemed to be intact on our biopsies at the time of 
implantation. The presence of living tissue is thought 
to confer an advantage of resistance to infection for 
this arterial substitute when compared with other 
prosthetic materials. 45As has been noted for vein 
allografts and other biologic arterial substitutes, we 
did observe one case of aneurysmal degeneration of
the vein allograft, n Also problematic s the high cost 
($2500 to $4500) of vein allografts. The routine use 
of vein allografts for infrageniculate bypass proce- 
dures cannot currently be recommended except in 
the case of an infected field and absence of any 
autogenous vein. 
CONCLUSION 
Vein allograft failure is in part mediated by rejec- 
tion invoMng both humoral (antibody) and cellular 
responses to vein allografts, which is not eliminated 
by low-dose azathioprine. This potentially correct- 
able cause of vein allograft failure may be improved 
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by better  match ing  of  donors  and recipients and by 
the use of  more  potent  immunosuppress ion .  Im-  
provement  in p rocurement  and preservat ion tech- 
n iques as well as adjunct ive use of  ant icoagulat ion 
may also augment  vein allograft patency and are the 
subjects o f  ongo ing  invest igat ion.  
We thank Clyde F. Barker, MD, for his advice and 
support hroughout the completion of this study. 
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